Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Dexmedetomidine for sedation in the ICU or PICU: a review of cost-effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response. 2014 Authors' conclusions Six economic evaluations and two guidelines were included in this review. All except one economic study showed that dexmedetomidine was associated with lower ICU and hospital costs. However, the clinical benefits were marginal and not consistent in the included studies. The included guidelines suggested that the use of dexmedetomidine might be preferred over the benzodiazepine sedatives for better clinical outcomes and lower risk of delirium. Indexing Status Subject indexing assigned by CRD MeSH Critical Care; Dexmedetomidine; Intensive Care Unitss; Precedex Language Published English Country of organisation Canada English summary An English language summary is available. Address for correspondence Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: requests@cadth.ca AccessionNumber 32016000162 Date abstract record published 28/01/2016 |